Company Overview

The Cigna Group, formerly Cigna Corporation (name changed February 2023), was founded in 1792 and operates as a global health services company headquartered in Bloomfield, Connecticut. As of September 2025, the company held a market capitalization of $80.82 billion and trades on the New York Stock Exchange under the ticker CI.

The Cigna Group ranked #15 in the 2023 Fortune 500 list of the largest U.S. corporations by total revenue and placed 68th in the 2023 Forbes Global 2000 ranking. The organization serves approximately 184 million customer relationships worldwide and maintains sales capabilities in more than 30 markets and jurisdictions, demonstrating its significant global reach in the healthcare sector.

Business Structure and Operations

The Cigna Group operates through two primary growth platforms that deliver its comprehensive healthcare services:

Evernorth Health Services

The Evernorth Health Services segment provides a suite of coordinated and point-solution health services. This includes pharmacy benefit management, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions, offered to health plans, employers, government organizations, and healthcare providers.

This segment has emerged as the company's primary growth engine. In 2024, pharmacy benefit services achieved an adjusted revenue of $111.8 billion, a substantial 46% increase from $76.8 billion in 2023. Concurrently, specialty and care services recorded $90.3 billion in adjusted revenue, marking an 18% rise from the previous year.

Cigna Healthcare

The Cigna Healthcare segment focuses on offering a range of health insurance products and services. This includes medical, pharmacy, behavioral health, dental, and other products for insured and self-insured customers. It also provides Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, alongside individual health insurance plans, and health care coverage in its international markets.

Financial Performance

2024 Full-Year Results

The Cigna Group delivered robust financial performance throughout 2024:

- Revenue Growth: Total revenues for 2024 increased by 27% to $247.1 billion.

- Net Income: Shareholders' net income for 2024 was reported at $3.4 billion, equating to $12.12 per share.

- Adjusted Operating Income: Adjusted income from operations saw a 4% increase from 2023, primarily driven by strong contributions from the Evernorth Health Services segment.

Customer Base Expansion

As of December 31, 2024, total customer relationships grew by 11% to 182.2 million. The total number of pharmacy customers increased by 20% to 118.3 million, attributed to new sales initiatives and the continued expansion of existing relationships.

Operational Efficiency Improvements

The adjusted Selling, General & Administrative (SG&A) expense ratio improved significantly to 5.9% for 2024, down from 7.3% in 2023. This enhancement in operational efficiency reflects successful business mix shifts and the impact of strong revenue growth.

Capital Management and Shareholder Returns

Share Repurchase Program

In 2024, the company repurchased approximately 20.9 million shares of common stock, amounting to $7.0 billion. The Board of Directors further approved an additional $6.0 billion in incremental share repurchase authorization, bringing the total share repurchase authority to $10.3 billion as of December 31, 2024.

Dividend Policy

The Company's Board of Directors declared a quarterly cash dividend of $1.51 per share, payable on March 20, 2025. This represents an 8% increase from the $1.40 per share quarterly dividend paid in 2024. The current dividend yield stands at 1.99%.

Recent Strategic Developments

Medicare Business Divestiture

The Cigna Group entered into a definitive agreement to sell its Medicare Advantage and related businesses to Health Care Service Corporation (HCSC) for an initial purchase price of $3.3 billion. This transaction, expected to close in the first quarter of 2025, will remove approximately $12 billion in revenue and aligns with the company's strategy to concentrate on its core business areas.

Investment in Specialty Pharmacy

Evernorth Health Services announced a $3.5 billion investment in Shields Health Solutions, a specialty pharmacy management company. This strategic investment further solidifies Evernorth's position in the rapidly growing specialty medicine market.

2025 Outlook and Projections

For the fiscal year 2025, The Cigna Group has provided the following guidance:

- Adjusted EPS: Adjusted Earnings Per Share (EPS) is projected to be a minimum of $29.60, indicating potential growth of at least 8.3% from the 2024 figure of $27.33.

- Evernorth Performance: Evernorth Health Services is anticipated to deliver adjusted income from operations of at least $7.2 billion.

- Cigna Healthcare: Cigna Healthcare is projected to contribute at least $4.1 billion, with an expected medical care ratio ranging between 83.2% and 84.2%.

Challenges and Market Position

While the company has demonstrated strong revenue growth, it has faced some operational challenges. Fourth-quarter 2024 results were notably impacted by higher-than-expected medical costs within the stop-loss product of the Cigna Healthcare segment. For the full year, the medical care ratio stood at 83.2%, which was above the initial guidance range.

Despite these near-term pressures, The Cigna Group maintains a strong market position. Its diversified healthcare services portfolio, robust cash generation capabilities, and strategic focus on high-growth areas like specialty pharmacy and comprehensive health solutions position it for continued success in the evolving healthcare landscape.